Fourth quarter | January-December |
|
|
Comment from the CEO
"It is with mixed feelings that we sum up 2023. Of course, we would have liked to see a better financial performance for the company, but it is gratifying that sales in
Order intake from our major partners has been disappointing in recent years, but I am confident that it will pick up once MDR certification and clinical outcomes are in place. Coupled with our efforts to establish collaborations with new partners and enter new markets, this will provide
Significant events during the quarter
- No significant events were reported during the quarter
Significant events after the quarter
- On
February 16, 2024 , the Board of Directors decided on a rights issue with preferential rights for existing shareholders of 27.4 MSEK before issue expenses. The purpose of the rights issue is to raise working capital for the operations, as well as creating a stable foundation for negotiations with stakeholders regarding expansion in existing and new markets.Enzymatica intends to secure the rights issue to 100 percent through subscription commitments and underwriting agreements.
Other events during and after the quarter
- On
November 30, 2023 ,Enzymatica changed its Certified Adviser toCarnegie Investment Bank AB , which acquiredErik Penser Bank , the former Certified Adviser for the company. -
On
January 8, 2024 ,Enzymatica's CEOClaus Egstrand appeared with ProfessorGlen Davison on the US morning TV show The Balancing Act, where the ongoing study at theUniversity of Kent was presented.
The full report is available on: www.enzymatica.com/investors/financial-reports
This information is information that
For more information, please contact:
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com
For more information, please visit www.enzymatica.se.
https://news.cision.com/enzymatica-ab/r/year-end-report-2023--scientific-and-regulatory-progress-generating-international-interest,c3930064
https://mb.cision.com/Main/18091/3930064/2609857.pdf
https://mb.cision.com/Public/18091/3930064/aecc2de492a6e99c.pdf
(c) 2024 Cision. All rights reserved., source